Friday, 14 Feb 2020

You are here

Limited Advantage to Very Early vs. Delayed Etanercept in RA

The VEDERA study sought to confirm whether the very early introduction of first-line etanercept+methotrexate (ETN+MTX) was superior to treat-to-target MTX (MTX-TT) in patients with early RA.

The study enrolled 120  treatment-naïve seropositive ERA (≤12 months symptom) patients with active disease (DAS28-ESR ≥3.2) and studied by clinical measures or ultrasound power Doppler (PD). Subjects receiving MTX-TT, were escalated to ETN if week 24 DAS28-ESR ≥2.6. The primary endpoint DAS28ESR remission was assessed at week 48.

The group was 71% female, 73% RF/84% ACPA positive, with a median symptom duration 20.3 and basedline DAS28 of 5.1 (1.1)).

Remission rates were:

Week 24                 Week 48

  • ETN+MTX= 38%                     52%
  • MTX-TT  = 33%                      38%    (ORs 1.6, 95% CI 0.8 to 3.5, p=0.211).

Sustained DAS28-ESR remission more likely with ETN+MTX versus MTX-TT (42% and 27%; p=0.035).

If ETN administered first line, there was an almost 3-fold increase odds (OR 2.84) of achieving remission, compared to starting ETN after 24 weeks of just MTX therapy.

While previous studies suggested that very early introduction of TNFI+MTX would have a larger beneficial effect, these studies failed to prove this contention, although giving ETN after failure of MTX-TT did yield lesser responses.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Alcohols Net Zero Effect in Rheumatoid Arthritis

A report from The National Databank for Rheumatic Disease addressed the impact of alcohol on disease activity and mortality in rheumatoid arthritis (RA) and found that alcohol use was not associated with changes in disease activity or mortality, after addressing confounders. 

DMARD Inertia by Registry Rheumatologists

A registry study of metric use (primarily RAPID3 and CDAI) in the treatment of rheumatoid arthritis (RA) patients shows that, even in the face of moderate or high disease activity, treatment changes by rheumatologists were relatively low (35.6–54.6%).

Bariatric Weight Loss Fails to Alter RA Risk

Obesity has been shown to be a risk factor for the onset of rheumatoid arthritis (RA) and also shown to affect outcomes by impairing responses to many DMARD therapies. A Swiss study of RA patients undergoing bariatric surgery failed to show that bariatric surgery and weight loss had any effect on the incidence of RA.

RheumNow Podcast- 2019 EULAR RA Guidelines (1.31.20)

Dr. Jack Cush reviews the news and journal articles from the past week on

Rheumatoid Arthritis Antibodies Linked With COPD

Women who were seropositive for anti-citrullinated protein antibodies (ACPA) and ultimately went on to develop rheumatoid arthritis (RA) were also at increased risk for being diagnosed with chronic obstructive pulmonary disease (COPD), analysis of data from the Nurses' Health Study showed.